Cipla is engaged in the Business of Pharmaceuticals.(Source : 202003 Annual Report Page No:157)
Financial Results:
Cipla Ltd reported Revenues for Q3FY25 of ₹7,073.00 Crores up from ₹6,604.00 Crore year on year, a rise of 7.1%.
Total Expenses for Q3FY25 of ₹5,379.00 Crores up from ₹5,119.00 Crores year on year, a rise of 5.08%.
Consolidated Net Profit of ₹1,575.00 Crores up 47.47% from ₹1,068.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹19.45, up 48.70% from ₹13.08 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
